AlphaMark Advisors’s VYNE Therapeutics VYNE Stock Holding History

AlphaMark Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-77	Closed	-$10K	–	569
2020 Q2	$10K	Buy	77 +52	+208%	+$7.04K	﹤0.01%	369
2020 Q1	$5K	Buy	+25	New	+$7.84K	﹤0.01%	389

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

AlphaMark Advisors's VYNE Position: Q3 2020 in Review

AlphaMark Advisors sold out of VYNE Therapeutics (VYNE) in Q3 2020, closing a stake of 77 shares — an estimated $10K sold.

AlphaMark Advisors first reported a position in VYNE in Q1 2020 and held it in 2 quarters. The position peaked at $10K in Q2 2020. 105 funds tracked by Wall St. Rank hold VYNE as of Q3 2020.

AlphaMark Advisors reported no remaining VYNE Therapeutics position as of Q3 2020 after selling out during the quarter.
AlphaMark Advisors sold 77 VYNE Therapeutics shares in Q3 2020, an estimated $10K.
AlphaMark Advisors first reported a position in VYNE Therapeutics in Q1 2020 and held it in 2 quarters.
AlphaMark Advisors's VYNE Therapeutics position peaked at $10K in Q2 2020.
105 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2020.

Based on AlphaMark Advisors's 13F filing for Q3 2020, filed 6 Nov 2020.